[Omail-admin-devel] Big Pharma is on the Searching for Options to Improve Their Pipeline .... Could Nuvilex, Inc. be Next?

[News R. <er...@rw...>]

Nuvilex  (OTCQB: N_V_L_X) has more than $25-million put into its
“Cell-in-a-Box™” technology, and as the company gets closer to the
beginning of its 3rd|third stage pancreas can cer testing, it may be
developing into a “gem” at just the right time!

If Big Pharma is on the searching for deals that can resupply their own
pipelines as long-time patents continue to expire, they’re surely
considering companies larger than Nuvilex. But, in turn, mid-level
companies are building their own pipelines this upgraded pipeline to the
“big boys.”

If the science proves out, Big Pharma can fly and acquire smaller
companies, like Nuvilex, Inc., circumventing a lot of the risks and the
great expenditure of time supplementing the early phases of development of
disease treatments.

The use of research materials circulated by the author is done at your own
risk.  You are encouraged to do your own research before making any
investment decision in regards to the secu rity discussed herein. The
author has not been rewarded by any entity in connection with the
distribution of these materials. You should assume that as of the date of
this report or letter, the author, possibly along with or through our
owners, affiliates, employees and/or consultants, (collectively referred to
as the author) has a position in all company shares (and/or options of the
shares) covered herein that is consistent with the position set forth in
our report. In connection with NVLX, the author has taken a long position.
Following the disbursement of any report or letter, the author intends to
continue engaging in trnsactns in the security covered herein, and we may
be long, short, and/or neutral at any time hereafter regardless of our
initial position and we preserve the right to procure or trade all or part
of our position at any time without notice.  This practice could end in our
trading securities at any time before, during, and/or after the
disbursement of this report. Read full disclaimer:
http://rwaped.org/link.php?M=32404335&N=1331&L=15&F=T

Unsub:http://rwaped.org/unsubscribe.php?M=32404335&C=5d4b8fd1f56cf2afa75e78fadbfe2a99&L=77&N=1331

10200 Forest Grn Boulevard, Suite 112, Louisville, Kentucky 40223